A Phase III clinical trial looked at 478 patients with high-risk low-grade glioma (LGG). The study compared a treatment of dose-dense temozolomide (TMZ) against standard radiotherapy (RT) to see which method better improved progression-free survival and overall survival.
The results showed no significant difference between the two treatment groups for the primary outcomes. For specific types of tumors, such as astrocytoma and oligodendroglioma, the survival times were similar between the two methods. However, the study did find a statistically significant difference in tumors without IDH mutations, where temozolomide showed a longer median survival compared to radiation.
Because this trial did not test combined-modality therapy, the results only compare these two treatments individually. While the trial provides high-certainty evidence for these specific comparisons, it is important to note that molecular classification of a tumor is now a key factor in understanding patient outlook. Patients should discuss these specific findings and their unique molecular profile with their medical team.
